Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
about
Oncolytic viruses as therapeutic cancer vaccinesDendritic Cells in Oncolytic Virus-Based Anti-Cancer TherapyOncolytic virotherapy for human malignant mesothelioma: recent advancesThe known unknowns of the human dendritic cell networkThe ex vivo purge of cancer cells using oncolytic viruses: recent advances and clinical implicationsTrial Watch:: Oncolytic viruses for cancer therapyThe plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functionsSensitivity of human pleural mesothelioma to oncolytic measles virus depends on defects of the type I interferon response.Measles to the Rescue: A Review of Oncolytic Measles VirusModular Three-component Delivery System Facilitates HLA Class I Antigen Presentation and CD8(+) T-cell Activation Against Tumors.The tumor-associated marker, PVRL4 (nectin-4), is the epithelial receptor for morbillivirusesViral oncolysis - can insights from measles be transferred to canine distemper virus?Oncolytic measles virus enhances antitumour responses of adoptive CD8+NKG2D+ cells in hepatocellular carcinoma treatment.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyOncolytic measles virus efficacy in murine xenograft models of atypical teratoid rhabdoid tumorsA measles virus selectively blind to signaling lymphocytic activation molecule shows anti-tumor activity against lung cancer cells.CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy.Oncolytic virus efficiency inhibited growth of tumour cells with multiple drug resistant phenotype in vivo and in vitro.Human plasmacytoid dendritic cells: from molecules to intercellular communication networkType I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response.Oncolytic virus-mediated reversal of impaired tumor antigen presentation.Antitumor Virotherapy by Attenuated Measles Virus (MV).Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Viral cancer therapies: are they ready for combination with other immunotherapies?Update on the role of plasmacytoid dendritic cells in inflammatory/autoimmune skin diseases.Therapy-induced microenvironmental changes in cancer.Potential and clinical translation of oncolytic measles viruses.Macrophage response to oncolytic paramyxoviruses potentiates virus-mediated tumor cell killing.Combined cytotoxic activity of an infectious, but non-replicative herpes simplex virus type 1 and plasmacytoid dendritic cells against tumour cells.Measles Edmonston vaccine strain derivatives have potent oncolytic activity against osteosarcoma.Attenuated measles virus controls pediatric acute B-lineage lymphoblastic leukemia in NOD/SCID mice.Natural oncolytic activity of live-attenuated measles virus against human lung and colorectal adenocarcinomas.Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation.Oncolytic measles virus induces tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by human myeloid and plasmacytoid dendritic cells.A distinct subset of plasmacytoid dendritic cells induces activation and differentiation of B and T lymphocytes.A subset of human plasmacytoid dendritic cells expresses CD8α upon exposure to herpes simplex virus type 1.Attenuated measles virus used as an oncolytic virus activates myeloid and plasmacytoid dendritic cells.Oncolytic Viruses-Interaction of Virus and Tumor Cells in the Battle to Eliminate CancerpDCs efficiently process synthetic long peptides to induce functional virus- and tumour-specific T-cell responses.Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles.
P2860
Q21245758-D846B310-889B-4736-BE11-DF2CBF370C8FQ26774345-8F81F1AA-DC9A-4483-955C-71C961DDCD85Q26826590-1E27945C-A3BD-42C7-9E0C-284F574C11A0Q26865854-3403EA30-5498-44CE-9F3F-D67DFF2396A4Q27002660-78C6E7F5-BF4E-4682-8BB8-C3377750D2D8Q27021951-01883F87-DFF3-4AE5-9E69-1AA00ED5F9C7Q27023380-95A1E7B7-21C6-4F5A-9C51-042D2E0EE2B5Q27340224-545D7141-F3B6-474D-933C-74D34090687FQ28072097-DF1130A5-1B62-4ADF-A9C9-20D7BC962F56Q30358614-6DB8AA8C-DB3A-4F35-BFFB-3703770FFD4CQ33820699-5FEF7033-5647-46FA-A814-19B5047571DDQ33820717-DDCE17A4-BE90-4ED1-A408-67EE37AE80DEQ33899522-876277C0-BD89-4E6F-802A-E0904057B415Q35657822-02124008-0BBC-4657-AFCB-D466CE270902Q36250723-14451010-BA13-4576-9376-AD4700098EE0Q36413058-20125856-9B3F-493F-B584-C36027D055B4Q36821243-FAB6EE4B-1FF9-438A-A8A8-056F0089A66AQ37185612-B5A28B43-7933-4B5F-AAA2-294DA2740E86Q38166716-DAA4A7FC-5D1B-472E-A2DD-65AD2F5A6F81Q38176613-F3B3E503-0F48-4931-A306-D6806BA2C0D0Q38208315-68F0AF17-F454-4815-9F03-054CCECB09DCQ38212137-7E2BF503-9B01-45DB-A46D-4D2E2E7D70C3Q38241666-EE763D2C-077D-47FA-B82A-CC99BAFBABD0Q38647011-42E6175C-F812-48CB-B952-30DC3B0C30DBQ38720050-9DA038EC-2868-4EC8-AAA1-0EF4D02E2DFAQ38756772-BD6F2CF5-F2F7-4D4C-81CD-A0FAFCA1A80AQ38764947-5C14582B-06AD-4759-B378-37E1A2A65733Q38804011-28538711-3FB6-46EC-BE24-E6CEB34178A6Q38850997-3FB233F7-4C88-4B56-942D-0B95F3224316Q38940653-177419AC-79DC-43E4-8A68-2A6724119FDCQ39008033-0ECABD32-DFAE-45B0-9F8C-886BE07D6735Q39467892-234D2D97-0839-4883-8F2F-E67A382CB8DDQ40200208-9A74F294-9F76-457E-8310-EF1B99FD7725Q40336053-63774C6A-D7D3-45EB-8823-98F23115AE17Q40342539-62AC9276-FA92-414A-81A3-F06F3D1DA135Q41155777-F760BC1F-69C9-4364-9F4D-22BE91EDC219Q41220068-550C8065-6ED5-4933-A64E-A3B5C28E4A47Q41699675-78147214-8C36-4BC6-8E20-F082775BD947Q42204967-08E34A0D-14B2-4835-A45F-14B34174F8E8Q45323818-57ECF9AE-A58D-4F6D-875E-D3456D22527F
P2860
Measles virus vaccine-infected tumor cells induce tumor antigen cross-presentation by human plasmacytoid dendritic cells.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@en
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@nl
type
label
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@en
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@nl
prefLabel
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@en
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@nl
P2093
P1476
Measles virus vaccine-infected ...... plasmacytoid dendritic cells.
@en
P2093
Chantal Combredet
David Roulois
Jean-Baptiste Guillerme
Jean-François Fonteneau
Jérémie Ménager
Marc Gregoire
Nicolas Boisgerault
P304
P356
10.1158/1078-0432.CCR-12-2733
P407
P577
2013-01-21T00:00:00Z